Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Research & Development (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Research & Development for 9 consecutive years, with $48.9 million as the latest value for Q1 2026.

  • For Q1 2026, Research & Development fell 17.2% year-over-year to $48.9 million; the TTM value through Mar 2026 reached $230.1 million, up 16.72%, while the annual FY2025 figure was $240.3 million, 38.92% up from the prior year.
  • Research & Development hit $48.9 million in Q1 2026 for Bicycle Therapeutics, down from $51.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $71.0 million in Q2 2025 and bottomed at $14.3 million in Q1 2022.
  • Average Research & Development over 5 years is $41.2 million, with a median of $40.1 million recorded in 2024.
  • Year-over-year, Research & Development skyrocketed 125.5% in 2023 and then fell 17.2% in 2026.
  • Bicycle Therapeutics' Research & Development stood at $24.7 million in 2022, then surged by 80.82% to $44.7 million in 2023, then grew by 11.37% to $49.8 million in 2024, then grew by 4.0% to $51.8 million in 2025, then dropped by 5.54% to $48.9 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $48.9 million, $51.8 million, and $58.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.